| Size | Price | Stock |
|---|---|---|
| 5mg | $38 | In-stock |
| 10mg | $60 | In-stock |
| 25mg | $80 | In-stock |
| 50mg | $96 | In-stock |
| 100mg | $132 | In-stock |
| 200mg | $180 | In-stock |
| 250mg | $220 | In-stock |
| 500mg | $336 | In-stock |
| 1g | $500 | In-stock |
| 5 g | Get quote | |
| 10 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-40354 |
| M.Wt: | 312.37 |
| Formula: | C16H20N6O |
| Purity: | >98 % |
| Solubility: | Ethanol : 2.5 mg/mL (ultrasonic);DMSO : ≥ 116.67 mg/mL |
Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury[1][2][3][4][5][6][7][8][9].
In Vitro:Tofacitinib (1000 nM; 3 days) (Tasocitinib) suppresses proliferation and Th17 cell differentiation of SKG mouse spleen CD4+ T cells in vitro[2].
Tofacitinib (5 days) suppresses differentiation of naïve SKG mouse lung-infiltrating cells into CD11b+ Gr1dim and CD11b+ CD11c+ cells, while increasing CD11bdim CD11c+ cell proportions in vitro[2].
Tofacitinib (5 days) facilitates expansion of MDSCs and suppresses BMDC differentiation from naïve SKG mouse bone marrow cells in vitro[2].
Tofacitinib (1 μM; 60 min) abrogates IL6-induced STAT3 phosphorylation and reduces fibrotic marker expression in neonatal foreskin primary fibroblasts[4].
Tofacitinib (2 μM; 24 h) alters gene expression in white adipocytes, generating a distinct Tofacitinib gene signature[4].
Tofacitinib (1 μM; 24 hr pre-incubation) inhibits IL-4-induced JAK/STAT6 signaling in primary murine bone marrow macrophages, but does not provide sustained inhibitory activity after a 72 hr washout period[5].
Tofacitinib selectively inhibits Janus kinases 1, Janus kinases 2, and Janus kinases 3 with functional specificity for Janus kinases 1 and Janus kinases 3 over Janus kinase 2, and suppresses cytokine-mediated immune cell activation and pro-inflammatory signaling in vitro[7].
In Vivo:Tofacitinib (10-75 mg/kg; i.g.; daily; 1 week) (Tasocitinib) alleviates LPS-induced depressive-like behaviors and associated hippocampal pathological changes, with 30 mg/kg showing robust efficacy in reducing microgliosis, normalizing cytokine levels, and restoring BDNF levels[1].
Tofacitinib (30 mg/kg; i.g.; daily; 13 days) effectively improves depressive-like behaviors, including social avoidance, in CSDS-induced mice[1].
Tofacitinib (10-75 mg/kg; i.g.; daily; 1 week) is well-tolerated and does not affect emotional status in normal mice[1].
Tofacitinib (30 mg/kg; i.p.; twice daily; 5 days/week; 5 weeks) reduces established skin fibrosis in male TSK1/+ mice on a C57BL/6 background[4].
Tofacitinib (20 mg/kg; i.p.; three times per week; 8 weeks) ameliorates zymosan-induced interstitial lung disease in male SKG mice by increasing lung MDSCs to 72.8% of total lung cells and reducing pathogenic Th17 cells, ILC1s, and GM-CSF+ ILCs[2].
Tofacitinib (1-10 mg/kg; i.g.; every 6 hours starting 2 hours post-CLP) improves the 7-day survival rate of CLP-induced septic rats to 70%, reduces acute lung injury, and inhibits the JAK-STAT/NF-κB pathway[3].
Tofacitinib (10 mg/kg; p.o.; daily; 8 weeks) prevents murine lupus manifestations, modulates innate and adaptive immune responses, improves vascular function, and restores lipoprotein homeostasis in lupus-prone MRL/lpr mice[8].
Tofacitinib (10 mg/kg; p.o.; daily; 6 weeks) ameliorates established murine lupus manifestations and modulates interferon responses in lupus-prone MRL/lpr mice[8].
Tofacitinib (10 mg/kg/day; i.g.; every 2 days; 2 weeks) relieves liver fibrosis in a mouse model of chronic autoimmune hepatitis[9].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.